ASH Clinical News December 2016 | Page 75

Common molecular genetic mutations in AML

FLT3
(ITD, TKD)
37%

53
TP

P
KR TEN
A
PH S 2%
F6 2%
AS
XL 3%
1
3%
ML
L-P
TD
5%
RUNX1
5%

2%

29%
1
M

NP

KIT 6%
%
1 7

IDH

H2

DN

8%

M

T3

A

ID

CEBPA 9%

10%

TET
2

8%

T1

8%

%

Adapted from
Patel 2012.5

S
NRA

W

23

Molecular genetic testing may be an important factor
that can be utilized to facilitate clinical decision-making4
References: 1. National Cancer Institute. SEER Stat Fact Sheets: Acute Myeloid Leukemia (AML). http://seer.cancer.gov/statfacts/html/
amyl.html. Accessed September 20, 2016. 2. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer.
2006;107(9):2099-2107. 3. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484-495. 4. Referenced
with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2016.
© National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed September 20, 2016. To view the most recent
and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN
GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 5. Patel JP,
Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med.
2012;366(12):1079-1089.

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2016 Novartis

9/16

MLA-1148431